Acrivon reports Q4/FY24 net loss $22.8M/$80.6M; ACR-368 endometrial cancer cORR 35% in BM+ patients

Acrivon Therapeutics, Inc.

Cash $184.6M as of Dec 31, 2024; runway extended into 2027.
ACR-368 in BM+ endometrial cancer: 35% cORR, 80% DCR; in relapsed patients cORR 50% with mDOR >10 months.
Phase 1 ACR-2316 cleared doses 1-2; dose 3 shows tumor shrinkage; target engagement confirmed.
Endometrial cancer prioritized; ovarian and bladder deprioritized due to competition/low BM+ rate.
R&D expenses $64.0M for FY24 vs $46.0M in FY23, driven by ACR-368 and ACR-2316 clinical trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.